Background: |
Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773). (Microbial infection) In case of FCV infection, plays a role in the ribosomal termination-reinitiation event leading to the translation of VP2 (PubMed:18056426). |
Applications: |
ELISA, IHC |
Name of antibody: |
EIF3L |
Immunogen: |
Fusion protein of human EIF3L |
Full name: |
eukaryotic translation initiation factor 3 subunit L |
Synonyms: |
EIF3EIP; EIF3S11; HSPC021; HSPC025; MSTP005; EIF3S6IP |
SwissProt: |
Q9Y262 |
ELISA Recommended dilution: |
5000-10000 |
IHC positive control: |
Human cervical cancer |
IHC Recommend dilution: |
40-200 |